Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Cancer cell or component thereof
Reexamination Certificate
2007-06-05
2007-06-05
Yu, Misook (Department: 1642)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Cancer cell or component thereof
C424S093300, C435S371000
Reexamination Certificate
active
11274856
ABSTRACT:
The present invention provides novel, isolated, tumor-associated antigens, and methods for identifying such antigens in a biological sample, and of screening for the presence of such an antigen in a biological specimen, wherein the tumor antigen identified reacts with serum from a subject treated with a vaccine comprising a cytokine and proliferation-incompetent tumor cells which express the tumor-associated antigen. Also provided are kits for carrying out the methods of the invention.
REFERENCES:
patent: 4931275 (1990-06-01), Shinitzky et al.
patent: 5078996 (1992-01-01), Conlon, III et al.
patent: 5098702 (1992-03-01), Zimmerman et al.
patent: 5637483 (1997-06-01), Dranoff et al.
patent: 5674486 (1997-10-01), Sobol et al.
patent: 5763155 (1998-06-01), Boon-Falleur et al.
patent: 5904920 (1999-05-01), Dranoff et al.
patent: 2004/0121300 (2004-06-01), Frey et al.
patent: WO 98/04282 (1998-02-01), None
O'Rourke, et al., Aust. N.A. Jour. Surg., vol. 67, No. 12, pp. 834-841, Abstract only, 1997.
Walczak, et al., Expert Opin. Investig. Drugs, vol. 11, No. 12, pp. 1737-1748, Abstract only, 2002.
Dummer, Curr. Opin. Investig. Drugs, vol. 2, No. 6, pp. 844-848, Abstract only, 2001.
O'Keefe, et al., Prostate, vol. 58, No. 2, pp. 200-210, 2004.
Darrow, et al., “The Role of HLA Class I Antigens in Recognition of Melanoma Cells by Tumor-Specific Cytotoxic T Lymphocytes”, The Journal of Immunology, vol. 142, No. 9, pp. 3329-3335, 1989.
Crowley, et al., “MHC-Restricted Recognition of Autologous Melanoma by Tumor-Specific Cytotoxic Cells”, Cancer Research, vol. 52, p. 394-399, 1992.
Belidegrum, et al., “Interleukin 2 Expanded Tumor-infiltrating Lymphocytes in Human Renal Cell Cancer: Isolation, Characterization, and Antitumor Activity”, Cancer Research, vol. 48, pp. 206-214, 1988.
Ikemoto, et al., “Clinical studies on cell-mediated immunity in patients with renal ell carcinoma: interleukin-2 and interferon-y production of lymphocytes”, Cancer Immunology Immunotherapy, vol. 34, pp. 289-293, 1992.
Urban, et al., “Tumor Antigens”, Annual Rev. Immunol., vol. 10, pp. 617-644, 1992.
van der Bruggen, et al., “A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma”, vol. 254, pp. 1643-1647, 1991.
Sanda, et al., “Demonstration of a Rational Strategy for Human Prostate Cancer Gene Therapy”, The Journal of Urology, vol. 151, pp. 622-628, 1994.
Asher, et al., “Murine Tumor Cells Transduced with the Gene for tumor Necrosis Factor-a”, the Journal of Immunology, vol. 146, pp. 3227-3234, 1991.
Havell, et al., “The Antitumor function of Tumor Necrosis Factor (TNF)”, Jour. Exp. Med., vol. 167, pp. 1067-1085, 1988.
Gansbacher et al., “Retroviral Vector-mediated γ-interferon Gene Transfer into Tumor Cells Generates Potent and Long Lasting Antitumor Immunity”, Cancer Research, vol. 50, pp. 7820-7825, 1990.
Ley, et al., “Interleukin 2-dependent activation of tumor-specific cytotoxic T lymphocytes in vivo”, Eur. Jour. Immunol., vol. 21, pp. 851-854, 1991.
Watanabe, et al., “Exogenous expression of mouse inteferon γ cDNA in mouse neuroblastoma C1300 cells results in reduced tumorigenicity by augmented anti-tumor immunity”, Proc. Natl. Acad. Sci. USA, vol. 86, pp. 9450-9460, 1989.
Gansbacher, et al., “Interleukin 2 Gene Transfer into Tumor Cell Abrogates Tumorigenicity and Induces Protective Immunity”, Jour. Exp. Med., vol. 172, pp. 1217-1224, 1990.
Gansbacher, et al., “Retroviral factors carrying both the IL-2 and the IFM-gamma gene induce potent anti-tumor response in murine tumors”, Proceedings of the American Association for Cancer Research, vol. 33, p. 351, 1992.
Tepper, et al., “Murine Interleukin-4 Displays Potent Anti-Tumor Activity in Vivo”, Cell, vol. 57, pp. 503-512, 1989.
Porgador, et al., “Interleukin 6 Gene Transfection into Lewis Lung Carcinoma Tumor Cells Suppresses the Malignant Phenotype and Confers Immunotherapeutic Competence against Parental Metastic Cells”, Cancer Research, vol. 52, pp. 3679-3686, 1992.
Forni, et al., “Helper strategy in tumor immunology: Expansion of helper lymphocytes and utilization of helper lymphokines for experimental and clinical immunotherapy”, Cancer and Metastasis Reviews, vol. 7, pp. 289-309, 1988.
Fearon, et al., “Interleukin-2 Production by Tumor Cells Bypasses T Helper Function in the Generation of an Antitumor Response”, Cell, vol. 60, pp. 397-403, 1990.
Arnico, et al., “Comparison of Phospatase Isoenzymes PAP and PSA with Bone Scan in Patients with Prostate Carcinoma”, Clinical Nuclear Medicine, vol. 16, pp. 643-648, 1991.
Gerber, et al., “Assessment of Value of Routine Bone Scans in Patients with Newly Diagnosed Prostate Cancer”, Urology, vol. 37, No. 5, pp. 418-422, 1991.
Borrello, et al., “A Universal Granulocyte-Macrophage Colony-Stimulating Factor-Producing Bystander Cell Line for Use in the Formulation of Autologous tumor Cell-Based Vaccines”, Human Gene Therapy, vol. 10, pp. 1983-1991, 1999.
Poehl, “The Mail Reproductive System: Prostatic Cell Lines”, Atlas of Human Tumor Cell Lines, Academic Press, Inc., pp. 387-407, 1994.
Hock, et al., “Interleukin 7 Induces CD4+ T Cell-dependent Tumor Rejection”, Jour. Exp. Med., vol. 174, pp. 1291-1298, 1991.
Pardoll, et al., “New strategies for enhancing the immunogenicity of tumors”, Current Opinion in Immunology, vol. 5, pp. 719-725, 1993.
Nelson, et al., “New Approaches to Adjuvant Therapy for Patients with Adverse Histopathologic Findings Following Radical Prostatectomy”, The Urologic Clinics of North America, vol. 23, No. 4,pp. 685-696, 1996.
Dranoff, et al., “Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity”, Proc. Natl. Acad. Sci. USA, pp. 3539-3543, 1993.
Porgador, et al., “Immunotherapy of Tumor Metastasis via Gene Therapy”, Nat. Immun., vol. 13, pp. 113-130, 1994.
Radrizzani, et al., “Lysis by interleukin 2-stimulated tumor-infiltrating lymphocytes of autologous and allogeneic tumor target cells”, Cancer Immunol. Immunother., vol. 28, pp. 67-73, 1989.
Belldegrum, et al., “Lymphokine mRNA profile and functional analysis of a human CD4+ clone with unique antitumor specificity isolated from renal cell carcinoma ascitic fluid”, Cancer Immunol. Immunother., vol. 31, pp. 1-10, 1990.
Koo, et al., “Autologous Tumor-Specific tytoxicity of Tumor-Infiltrating Lymphocytes Derived from Human Renal Cell Carcinoma”, Journal of Immunotherapy, vol. 10, pp. 347-354, 1991.
Devita, et al., “Chapter 4: Biology fo Cytokines: The Interleukins”, “Chapter 5: Principles of Cell Killing by Bioogical Agents”, “Chapter 6: Principles of Tumor Immunity: Immunocompetence and Cancer”, Biological Therapy of Cancer, 5 Lippincott Co., pp. 87-118, 1991.
Joannides, et al., Immunology, vol. 37, pp. 413-442, 1993.
Harlow, et al., Antibodies, A Laboratory Manual, Cold Spring Harbor Laboratories, pp. 61-67, 1988.
Alexander, et al., J. Cancer, vol. 45, p. 119, 1990.
Simons, et al., “Induction of Immunity to Prostate Cancer Antigens: Results of a Clinical Trial of Vaccination with Irradiated Autologous Prostate Tumor Cells Engineered to Secrete Granulocyte-Macrophage Colony-stimulating Factor Using ex Vivo Gene Transfer”, Cancer Research, vol. 59, pp. 5160-5168, 1999.
Soiffer, et al., “vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma”, Proc. Natl. Acad. Sci. USA, vol. 95, pp. 1314-13146, 1998.
Hersey, et al., “Western Blot Analysis of
Ando Dale
Chang Ju-Fay
McArthur James
Nelson William
Roberts Margo
Cell Genesys Inc.
DLA Piper (US) LLP
Yu Misook
LandOfFree
Cancer-associated antigens and methods of their... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cancer-associated antigens and methods of their..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cancer-associated antigens and methods of their... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3823801